When to Order Imaging for Assessment of Cardiac Function and Baseline Cardiac Risk Stratification in Oncology Patients: ACR Appropriateness Decoded

When to Order Imaging for Assessment of Cardiac Function and Baseline Cardiac Risk Stratification in Oncology Patients: ACR Appropriateness Decoded

An oncologist refers a patient newly diagnosed with breast cancer who is scheduled to begin a regimen including an anthracycline. The patient has a history of hypertension but is otherwise asymptomatic from a cardiac standpoint. Before initiating a potentially cardiotoxic therapy, you need to establish a baseline left ventricular ejection fraction (LVEF) and assess overall cardiac risk. Do you order a transthoracic echocardiogram (TTE), a cardiac MRI, or a nuclear medicine ventriculography (MUGA) scan? Choosing the right initial imaging is critical for safe and effective cancer treatment. This guide decodes the American College of Radiology (ACR) Appropriateness Criteria to help you select the most suitable study for your patient.

What Does ACR Assessment of Cardiac Function and Baseline Cardiac Risk Stratification in Oncology Patients Cover?

This ACR guideline focuses on the use of noninvasive cardiac imaging for two primary clinical situations in adult oncology patients: the initial, baseline assessment of cardiac function before starting potentially cardiotoxic cancer therapy, and the evaluation of cardiac function in patients who develop cardiac symptoms during their treatment. The recommendations are designed to help clinicians establish a functional baseline, identify pre-existing cardiac issues that could increase treatment risk, and investigate new symptoms that may indicate cardiotoxicity or ischemia.

These criteria specifically apply to initial imaging for these scenarios. They do not cover routine surveillance imaging in asymptomatic patients during or after therapy, nor do they address the workup for other specific oncologic complications like pericardial effusion or pulmonary embolism, which are covered under separate ACR guidelines. The focus is on assessing myocardial function and stratifying risk directly related to the initiation or continuation of cancer treatment.

What Imaging Should I Order for Assessment of Cardiac Function and Baseline Cardiac Risk Stratification in Oncology Patients? Recommendations by Clinical Scenario

The ACR provides specific recommendations based on the patient’s clinical context, primarily distinguishing between asymptomatic baseline assessment and the evaluation of new symptoms during therapy.

For an adult undergoing cardiac risk stratification prior to initiation of oncologic therapy with no cardiac symptoms, the primary goal is to establish a baseline LVEF. For this initial imaging, the ACR rates several noninvasive studies as Usually Appropriate. Transthoracic resting echocardiography (TTE) is often the first choice due to its wide availability, lack of ionizing radiation, and excellent ability to assess ventricular function, valvular integrity, and hemodynamics. Cardiac MRI (CMR), both with and without IV contrast, is also rated as Usually Appropriate and is considered the gold standard for quantifying ventricular volumes and LVEF due to its high accuracy and reproducibility. Nuclear medicine ventriculography (MUGA scan) is another Usually Appropriate option that provides a reliable LVEF measurement, though it involves radiation exposure.

For an adult patient who develops cardiac symptoms during oncologic therapy where ischemia is not excluded, the diagnostic possibilities are broader, and the imaging recommendations reflect this. In this scenario, a transthoracic resting echocardiogram remains Usually Appropriate to quickly assess for changes in LVEF or new wall motion abnormalities. However, because ischemia is a concern, several other modalities are also considered Usually Appropriate. These include stress echocardiography, stress cardiac MRI (with and without contrast), and Coronary CT Angiography (CTA) to evaluate for coronary artery disease. Nuclear medicine stress tests, such as Rb-82 PET/CT and SPECT, are also Usually Appropriate for assessing myocardial perfusion and viability.

ACR Imaging Recommendations Table

Adult vs. Pediatric Assessment of Cardiac Function and Baseline Cardiac Risk Stratification in Oncology Patients Imaging: Radiation Dose Tradeoffs

While the clinical scenarios provided focus on adults, the principles of cardiac assessment in pediatric oncology are similar but carry a greater emphasis on minimizing radiation exposure. Children and adolescents are inherently more sensitive to the long-term effects of ionizing radiation, and their longer life expectancy provides more time for potential stochastic effects, such as secondary malignancies, to develop. Consequently, the As Low As Reasonably Achievable (ALARA) principle is paramount.

For pediatric patients, non-ionizing modalities like transthoracic echocardiography and cardiac MRI are strongly preferred for both baseline and follow-up assessments of cardiac function. When a study involving radiation, such as a nuclear medicine ventriculography or a cardiac CT, is deemed medically necessary, protocols must be specifically tailored to the pediatric patient to reduce the dose. The relative radiation level (RRL) often reflects this, with some studies falling into a higher radiation category for children than for adults for an equivalent procedure (e.g., ☢ ☢ ☢ ☢ for pediatrics vs. ☢ ☢ ☢ for adults), underscoring the higher relative biological risk and the need for careful justification and optimization.

Imaging Protocol Details for Assessment of Cardiac Function and Baseline Cardiac Risk Stratification in Oncology Patients

Once you’ve decided on the right study, the specific imaging protocol is essential for obtaining diagnostic-quality results. Key parameters like contrast timing in a cardiac MRI, strain imaging views in an echocardiogram, or gating techniques in a cardiac CT can significantly impact the accuracy of the functional assessment. While specific protocol guides for this topic are not available, our comprehensive library contains detailed, evidence-based protocols for many of the imaging modalities recommended by the ACR. These guides cover technique, contrast administration, patient preparation, and interpretation principles to help ensure you acquire the necessary information to guide patient care.

Tools to Help You Order the Right Study

Navigating imaging guidelines and radiation safety can be complex. GigHz offers a suite of free, straightforward tools designed to support clinical decision-making for ordering physicians and trainees.

• ACR Appropriateness Criteria Lookup: For clinical questions beyond cardiac risk in oncology, this tool provides direct access to the full, searchable ACR guidelines, covering thousands of clinical scenarios to help you choose the right test every time.

• Imaging Protocol Library: After selecting a study, consult our library for detailed, step-by-step protocols. These guides are designed to help ensure the imaging is performed correctly to answer the clinical question.

• Radiation Dose Calculator: This tool helps you estimate and track cumulative radiation exposure for your patients. It’s an invaluable resource for communicating with patients about the risks and benefits of imaging and for adhering to ALARA principles.

Frequently Asked Questions

Why is transthoracic echocardiography (TTE) so often the first choice for baseline cardiac assessment in oncology patients?

Transthoracic echocardiography is rated “Usually Appropriate” and is frequently the initial test because it is noninvasive, widely available, cost-effective, and uses no ionizing radiation. It provides excellent real-time information on left and right ventricular systolic function (including LVEF), diastolic function, valvular integrity, and pericardial disease, addressing the key questions for pre-therapy risk stratification.

When should I consider a cardiac MRI (CMR) instead of an echocardiogram for baseline assessment?

A cardiac MRI may be preferred when a patient has poor acoustic windows on an echocardiogram, leading to a suboptimal or non-diagnostic study. CMR is also considered the gold standard for quantifying ventricular volumes and ejection fraction due to its superior spatial resolution and reproducibility, making it an excellent choice for serial monitoring where small changes in LVEF are clinically significant.

What is the role of a MUGA scan in modern cardio-oncology?

A nuclear medicine ventriculography, or MUGA scan, is a highly reproducible method for measuring LVEF and was historically a primary tool in cardio-oncology. While it is still rated “Usually Appropriate” for baseline assessment, its use has declined in favor of non-ionizing methods like echo and MRI. It remains a valuable option if local expertise in quantitative echo or CMR is limited or if those modalities are contraindicated.

If a patient on chemotherapy develops chest pain, why does CTA of the coronary arteries become “Usually Appropriate”?

Certain chemotherapeutic agents can accelerate atherosclerosis or induce vasospasm, increasing the risk of acute coronary syndromes. When a patient on therapy develops symptoms concerning for ischemia (like chest pain), the diagnostic priority shifts to include ruling out coronary artery disease. A Coronary CTA is a noninvasive way to visualize the coronary arteries and is rated “Usually Appropriate” in this context, alongside functional stress tests.

Are there any situations where a simple chest radiograph is sufficient?

For the specific question of assessing cardiac function and baseline risk, a chest radiograph is rated “Usually Not Appropriate” for an asymptomatic patient and “May be appropriate (Disagreement)” for a symptomatic patient. While it can show cardiomegaly or signs of heart failure like pulmonary edema, it does not directly measure LVEF or assess for ischemia. It is more useful for evaluating for alternative causes of symptoms, such as pneumonia or a pleural effusion, rather than as a primary tool for cardiac functional assessment in this setting.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 12, 2026